“It is vital that policymakers reform Medicare to ensure that seniors receive the full value of low-cost generics and the full value of their Part D benefit,” said Dan Leonard, president and CEO of the US Association for Accessible Medicines, as he pointed out that the latest AAM-sponsored study by researcher Avalere Health has highlighted the continued worsening of generic drug coverage in Medicare Part D.
The 2021 Avalere study found that Medicare Part D plans place generic prescription drugs on generic tiers 45% of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?